Ajanta Pharma Limited — Investor Meet, 05-05-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Ajanta Pharma discussed steady revenue growth and strong EBITDA margins for Q4 and the full year. Management emphasized specialty formulations and export market expansion as growth drivers. They highlighted robust order execution, a healthy pipeline, and ongoing efficiency improvements. The overall tone was confident about sustaining momentum and strategic focus areas.